CIK 0001093557 · Large accelerated filer
DEXCOM INC
Sign in to watch- Ticker
- DXCM
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330857544
- Phone
- 8582000200
- Business address
- 6340 SEQUENCE DRIVE, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,328,435
- in 8 filings, $4.3M under 10b5-1 plans
Net −$4,328,435. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- SAYER KEVIN R −$2.4M Executive Chair sold 8% of stake
- AUGUSTINOS NICHOLAS −$680K Director sold 22% of stake
- Stern Sadie −$649K EVP Chief People & Culture Off sold 6% of stake
- Sylvain Jereme M −$303K EVP, Chief Financal Officer sold 2% of stake
- Brown Michael Jon −$288K EVP Chief Legal Compliance Off sold 3% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-09 | Pacelli Steven Robert Managing Dir., Dexcom Ventures | Returned to the company | −932 | $406.06 | $378K | 37,105 |
| 2022-03-09 | Pacelli Steven Robert Managing Dir., Dexcom Ventures | Returned to the company | −1,180 | $406.06 | $479K | 35,925 |
| 2022-03-09 | Leach Jacob Steven EVP Chief Technology Officer | Returned to the company | −1,317 | $406.06 | $535K | 77,702 |
| 2022-03-09 | Leach Jacob Steven EVP Chief Technology Officer | Returned to the company | −2,065 | $406.06 | $839K | 75,637 |
| 2022-03-09 | Leach Jacob Steven EVP Chief Technology Officer | Returned to the company | −891 | $406.06 | $362K | 74,746 |
| 2022-03-09 | Flynn Paul R EVP Global Revenue | Returned to the company | −1,069 | $406.06 | $434K | 18,081 |
| 2022-03-09 | Flynn Paul R EVP Global Revenue | Returned to the company | −1,114 | $406.06 | $452K | 16,967 |
| 2022-03-09 | Flynn Paul R EVP Global Revenue | Returned to the company | −784 | $406.06 | $318K | 16,183 |
| 2022-03-09 | Dolan Matthew Vincent SVP Corporate Development | Returned to the company | −393 | $406.06 | $160K | 10,042 |
| 2022-03-09 | Dolan Matthew Vincent SVP Corporate Development | Returned to the company | −192 | $406.06 | $78K | 9,850 |
| 2022-03-09 | Dolan Matthew Vincent SVP Corporate Development | Returned to the company | −489 | $406.06 | $199K | 9,361 |
| 2022-03-09 | Dolan Matthew Vincent SVP Corporate Development | Returned to the company | −541 | $406.06 | $220K | 8,820 |
| 2022-03-09 | Balo Andrew K EVP, Global Medical Affairs | Returned to the company | −932 | $406.06 | $378K | 18,113 |
| 2022-03-09 | Balo Andrew K EVP, Global Medical Affairs | Returned to the company | −1,549 | $406.06 | $629K | 16,564 |
| 2022-03-09 | Balo Andrew K EVP, Global Medical Affairs | Returned to the company | −949 | $406.06 | $385K | 15,615 |
| 2022-03-09 | Abbey Donald EVP Quality Regulatory Affairs | Returned to the company | −1,317 | $406.06 | $535K | 52,341 |
| 2022-03-09 | Abbey Donald EVP Quality Regulatory Affairs | Returned to the company | −932 | $406.06 | $378K | 51,409 |
| 2022-03-09 | Abbey Donald EVP Quality Regulatory Affairs | Returned to the company | −1,180 | $406.06 | $479K | 50,229 |
| 2022-03-08 | Sylvain Jereme M EVP, Chief Financial Officer | Grant or award | +5,297 | $0.00 | $5 | 19,959 |
| 2022-03-08 | Stern Sadie EVP Chief Human Resources Off | Grant or award | +5,297 | $0.00 | $5 | 18,758 |
Page 25 of 40 · 785 trades